Glaukos Corp
$
77.6
0.26 (0.33%)
| Volume: | 99,551 | Avg Vol (1m): | 390,608 |
| Market Cap $: | 2.82 Bil | Enterprise Value $: | 2.67 Bil |
| P/E (TTM): | 0.00 | P/B: | 15.11 |
| Earnings Power Value | 5.83 |
| Net Current Asset Value | 3.9 |
| Tangible Book | 5.12 |
| Projected FCF | 0 |
| Median P/S Value | 51.37 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 7/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | No Debt |
Cash-To-Debt ranked
higher than
82.44%
of
205
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 10000, Med: 1.74, Min: 0.01
GKOS:
No Debt
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 0.12, Med: 10000, Max: 10000
Current: 10000
|
| Equity-to-Asset | 0.81 |
Equity-to-Asset ranked
higher than
82.14%
of
196
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 2.26, Med: 0.6, Min: -5.6
GKOS:
0.81
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: -5.81, Med: 0.85, Max: 0.89
Current: 0.81
|
| Piotroski F-Score | 4 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 34.77 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -1.58 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC -38.1%
WACC 12.9%
| ||
Profitability & Growth : 5/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | -5.75 |
Operating Margin ranked
lower than
60.70%
of
201
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 239.27, Med: 4.41, Min: -219137.5
GKOS:
-5.75
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: -67.78, Med: -10.77, Max: 3.71
Current: -5.75
|
| Net Margin % | -5.93 |
Net Margin ranked
lower than
60.70%
of
201
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 182.67, Med: 4.18, Min: -221450
GKOS:
-5.93
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: -60.34, Med: -16.87, Max: 3.95
Current: -5.93
|
| ROE % | -7.11 |
ROE ranked
lower than
60.61%
of
198
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 95.67, Med: 5.43, Min: -1452.51
GKOS:
-7.11
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: -8.3, Med: -0.07, Max: 4.26
Current: -7.11
|
| ROA % | -6.03 |
ROA ranked
lower than
58.25%
of
206
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 46.82, Med: 1.85, Min: -307.58
GKOS:
-6.03
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: -52.2, Med: -23.94, Max: 3.6
Current: -6.03
|
| ROC (Joel Greenblatt) % | -41.76 |
ROC (Joel Greenblatt) ranked
lower than
67.16%
of
204
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 387.24, Med: 9.63, Min: -114200
GKOS:
-41.76
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: -1308.7, Med: -377.19, Max: 45.47
Current: -41.76
|
| 3-Year Total Revenue Growth Rate | 36.20 |
3-Year Revenue Growth Rate ranked
higher than
94.12%
of
170
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 1424.9, Med: 4.1, Min: -100
GKOS:
7.8
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: 7.8, Med: 36.2, Max: 55
Current: 7.8
|
| 3-Year Total EBITDA Growth Rate | 41.10 |
3-Year EBITDA Growth Rate ranked
lower than
100.00%
of
155
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 426.6, Med: 10, Min: -759
GKOS:
53.4
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
|
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: 53.4
Current: 53.4
|
| 3-Year EPS w/o NRI Growth Rate | 44.20 |
3-Year EPS w/o NRI Growth Rate ranked
higher than
97.42%
of
155
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 253, Med: 12.9, Min: -782.7
GKOS:
44.2
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
|
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 44.2, Max: 81.9
Current: 44.2
|
» GKOS's 30-Y Financials
Financials (Next Earnings Date: 2019-08-02)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NYSE:GKOS
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Medical Instruments & Equipment » Medical Instruments & Supplies   NAICS : 339112   SIC : 3841 |
| Compare | NAS:OSUR SZSE:300677 LSE:AMS SZSE:300595 NAS:ATRI XMCE:FAE NAS:LMNX TSE:7730 TSE:7780 TSE:3593 SZSE:300358 SZSE:300171 XKLS:7153 SZSE:300061 NAS:ATRC NAS:LMAT SHSE:603222 SZSE:002414 XKRX:145720 XKRX:048260 |
| Traded in other countries | 6GJ.Germany |
| Address | 229 Avenida Fabricante, San Clemente, CA, USA, 92672 |
| Glaukos Corp is an ophthalmic medical technology company that develops and commercializes products and procedures used to treat glaucoma. The firm receives virtually all of its revenue from sales of its iStent products, which are primarily sold to hospitals and surgery centers. The iStent is a micro-invasive glaucoma surgery device that reduces intraocular pressure by restoring the natural outflow pathways for aqueous humor, the thin fluid that circulates the eye. It can lower pressure in adult patients with mild to moderate open-angle glaucoma. Glaukos generates the vast majority of its revenue in the United States. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 15.11 |
PB Ratio ranked
lower than
84.46%
of
193
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 53.91, Med: 3.45, Min: 0.13
GKOS:
15.11
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 5.19, Med: 9.88, Max: 16.17
Current: 15.11
|
| PS Ratio | 14.18 |
PS Ratio ranked
lower than
77.08%
of
192
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 720.69, Med: 3.48, Min: 0.08
GKOS:
14.18
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 1.97, Med: 9.41, Max: 15
Current: 14.18
|
| Price-to-Free-Cash-Flow | 174.79 |
Price-to-Free-Cash-Flow ranked
lower than
82.43%
of
74
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 794.44, Med: 28.61, Min: 0.95
GKOS:
174.79
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
|
Price-to-Free-Cash-Flow range over the past 10 years
Min: 46.05, Med: 201.19, Max: 635.64
Current: 174.79
|
| Price-to-Operating-Cash-Flow | 108.61 |
Price-to-Operating-Cash-Flow ranked
lower than
82.98%
of
94
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 807.55, Med: 21.15, Min: 0.86
GKOS:
108.61
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
|
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 34.95, Med: 105.7, Max: 329.81
Current: 108.61
|
| EV-to-EBIT | -238.10 |
EV-to-EBIT ranked
lower than
100.00%
of
121
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 126.36, Med: 23.93, Min: 0.21
GKOS:
-238.1
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: -2890.1, Med: -144.9, Max: 482.6
Current: -238.1
|
| EV-to-EBITDA | -496.64 |
EV-to-EBITDA ranked
lower than
97.83%
of
138
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 614.98, Med: 19.49, Min: 0.2
GKOS:
-496.64
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: -8497.5, Med: -13.5, Max: 573.9
Current: -496.64
|
| EV-to-Revenue | 13.78 |
EV-to-Revenue ranked
lower than
70.35%
of
199
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 4881, Med: 3.57, Min: 0.12
GKOS:
13.78
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 0.1, Med: 9.8, Max: 14.5
Current: 13.78
|
| Current Ratio | 6.72 |
Current Ratio ranked
higher than
80.50%
of
200
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 30.7, Med: 2.57, Min: 0.1
GKOS:
6.72
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 0.52, Med: 6.01, Max: 8.45
Current: 6.72
|
| Quick Ratio | 6.23 |
Quick Ratio ranked
higher than
85.07%
of
201
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 30.69, Med: 1.87, Min: -1.52
GKOS:
6.23
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 0.41, Med: 5.72, Max: 7.94
Current: 6.23
|
| Days Inventory | 184.84 |
Days Inventory ranked
lower than
57.36%
of
197
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 876.25, Med: 124.35, Min: 0.86
GKOS:
184.84
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 65.71, Med: 140.03, Max: 266.8
Current: 184.84
|
| Days Sales Outstanding | 38.57 |
Days Sales Outstanding ranked
higher than
84.24%
of
165
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 655.77, Med: 61.97, Min: 1
GKOS:
38.57
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 37.6, Med: 40.83, Max: 50.4
Current: 38.57
|
| Days Payable | 78.46 |
Days Payable ranked
higher than
80.13%
of
151
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 713.41, Med: 54.66, Min: 2
GKOS:
78.46
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 66.94, Med: 103.67, Max: 480.19
Current: 78.46
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -3.10 |
3-Year Share Buyback Rate ranked
lower than
73.43%
of
143
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 9.1, Med: -5, Min: -273.3
GKOS:
-3.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -11.6, Med: -10.9, Max: -3.1
Current: -3.1
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 15.13 |
Price-to-Tangible-Book ranked
lower than
71.86%
of
167
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 3100, Med: 4.77, Min: 0.22
GKOS:
15.13
Ranked among companies with meaningful Price-to-Tangible-Book only.
|
Price-to-Tangible-Book range over the past 10 years
Min: 6.14, Med: 10.14, Max: 15.3
Current: 15.13
|
| Price-to-Median-PS-Value | 1.51 |
Price-to-Median-PS-Value ranked
higher than
67.50%
of
160
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 4.9, Med: 1.13, Min: 0.01
GKOS:
1.51
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.23, Med: 1.04, Max: 1.59
Current: 1.51
|
| Earnings Yield (Joel Greenblatt) % | -0.42 |
Earnings Yield (Greenblatt) ranked
lower than
60.87%
of
207
companies
in the
Medical Instruments & Supplies
industry.
Industry Max: 476.19, Med: 2.4, Min: -3333.33
GKOS:
-0.42
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: -8390.6, Med: -0.5, Max: 2841.8
Current: -0.42
|
More Statistics
| Revenue (TTM) (Mil) $ | 195.17 |
| EPS (TTM) $ | -0.34 |
| Beta | 1.78 |
| Volatility % | 73.42 |
| 52-Week Range $ | 36.89 - 83.14 |
| Shares Outstanding (Mil) | 36.4 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 4 |
| Positive ROA | N |
| Positive CFROA | Y |
| Higher ROA yoy | N |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | Y |